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Abstract
Background: TGFb is both neuroprotective and a key immune system modulator and is likely to be an important
target for future stroke therapy. The precise function of increased TGF-b1 after stroke is unknown and its
pleiotropic nature means that it may convey a neuroprotective signal, orchestrate glial scarring or function as an
important immune system regulator. We therefore investigated the time course and cell-specificity of TGFb
signaling after stroke, and whether its signaling pattern is altered by gender and aging.
Methods: We performed distal middle cerebral artery occlusion strokes on 5 and 18 month old TGFb reporter
mice to get a readout of TGFb responses after stroke in real time. To determine which cell type is the source of
increased TGFb production after stroke, brain sections were stained with an anti-TGFb antibody, colocalized with
markers for reactive astrocytes, neurons, and activated microglia. To determine which cells are responding to TGFb
after stroke, brain sections were double-labelled with anti-pSmad2, a marker of TGFb signaling, and markers of
neurons, oligodendrocytes, endothelial cells, astrocytes and microglia.
Results: TGFb signaling increased 2 fold after stroke, beginning on day 1 and peaking on day 7. This pattern of
increase was preserved in old animals and absolute TGFb signaling in the brain increased with age. Activated
microglia and macrophages were the predominant source of increased TGFb after stroke and astrocytes and
activated microglia and macrophages demonstrated dramatic upregulation of TGFb signaling after stroke. TGFb
signaling in neurons and oligodendrocytes did not undergo marked changes.
Conclusions: We found that TGFb signaling increases with age and that astrocytes and activated microglia and
macrophages are the main cell types that undergo increased TGFb signaling in response to post-stroke increases in
TGFb. Therefore increased TGFb after stroke likely regulates glial scar formation and the immune response to
stroke.
Background
Transforming Growth Factor b1 (TGF-b1) is universally
induced by acute and chronic brain injury, including
stroke, trauma, seizure, multiple sclerosis, and Alzhei-
mer’s disease [1]. TGFb is highly conserved and in
mammals exists as three isoforms that bind to the same
receptors; TGF-b1, TGF-b2 and TGF-b3. TGF-b1i st h e
isoform typically induced by injury [2]. In the brain,
TGFb receptors are present on all major cell types [3].
However, both TGFb activation and signaling are
extensively regulated and due to this its effects are typi-
cally pleiotrophic and context-dependent. Therefore,
after brain injury the biological effects of TGFb signaling
are likely influenced by both injury type and timing.
After brain injury, TGFb signaling can be neuropro-
tective, but also promote glial scarring and fibrosis
[1,4-6]. While neuroprotection is undoubtedly desirable,
glial scarring and fibrosis are less likely to be advanta-
geous. In addition, TGFb’s have potent effects on the
immune system. TGF-b1 can be stimulatory or inhibi-
tory depending on the cell type, cytokine milieu and dif-
ferentiation state of the responding cell and can have
both pro- and anti-inflammatory effects [7]. It is not
known which subset of these roles TGF-b1 plays when
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ferent types of brain injury.
In stroke, TGF-b1 mRNA is elevated for at least a
week afterwards [8] and clearly exerts a neuroprotective
role. When overexpressed, TGF-b1 limits stroke size
[4,9,10]. And when TGFb signaling is blocked, ischemic
damage is exacerbated [11]. Because of this, it may be
an effective therapeutic agent for stroke. Developing
new therapeutic agents to treat those affected by stroke
is critical. The elderly segment of the American popula-
tion is rapidly increasing and 70% of the deaths of indi-
viduals over 65 are attributable to cardiovascular disease
[ 1 2 ] .B u ti no r d e rt od e v e l o pT G F b as a therapeutic
agent, it is necessary to understand if it plays any addi-
tional roles in the brain after stroke.
We therefore investigated the timecourse and cell-
specificity of TGFb signaling after stroke, and whether
its signaling pattern is altered by gender and aging in a
mouse model of stroke. We report here that TGFb sig-
naling increases 2 fold after the dMCAO model of
stroke, beginning on day 1 and peaking on day 7. This
pattern of increase is similar in each gender and pre-
served in old animals, although absolute TGFb signaling
was much higher in the brains of the aged animals.
CD68+ activated microglia and macrophages were the
predominant source of increased TGF-b1a f t e rs t r o k e
and astrocytes and CD68+ cells were the main cell
types that responded to the post-stroke increase in
TGF-b1. Our results demonstrate that TGFb signaling
peaks at 7 days after dMCAO stroke, increases with
aging, and that the cells with increased responses during
this time period, astrocytes and microglia, are those
involved in glial scarring and innate immune responses.
This may indicate that TGFb signaling plays a role in




SBE-LucRT mice were a gift from Dr Tony Wyss-Coray
[13]. Nine females and 5 males (5 months old) were
used to gauge variability in bioluminescence between
individual mice, and to determine if bioluminescence is
affected by the estrus cycle. Eighteen young females (5
months old) and eighteen old females (18 months old)
were used to measure TGFb signaling after stroke in
real time by bioluminescence. 3 mice from each cohort
were sacrificed at days 1, 3, 7, 14 and 21 after stroke for
localization of TGF-b1a n dT G F b signaling by immuno-
florescence. Three mice of each age group also under-
went sham surgery and were imaged for 21 days prior
to sacrifice for localization of TGFb signaling in unin-
jured brains. This experimental paradigm was repeated
in young and old male mice.
Surgery
Distal middle cerebral artery occlusion (dMCAO) was
induced as described previously [14]. Briefly, mice were
anesthetized by isoflurane inhalation (2% isoflurane in
100% oxygen) and the skin over the right temple was
shaved. Skin was swabbed with chlorehexidine and an
incision was made to expose the temporalis muscle. A
pocket was created in the temporalis muscle to expose
the skull underneath and the right middle cerebral
artery (MCA) was identified. A microdrill was used to
penetrate the skull and expose the underlying MCA.
The meninges were cut and the vessel was ligated using
a small vessel cauterizer. The temporalis muscle was
replaced and the wound closed using surgical glue.
Throughout surgery body temperature was maintained
at 37°C using a feedback controlled heating blanket.
Bioluminescent imaging
Bioluminescence was detected as described previously
using the In Vivo Imaging System (IVIS; Xenogen, Ala-
meda, CA) [13]. Mice were injected intraperitoneally
with 150 mg/kg D-luciferin (Xenogen) 10 min before
imaging and anesthetized with isoflurane during ima-
ging. Photons emitted from living mice were acquired as
photons per second per cm
2 per steradian (sr) by using
LIVINGIMAGE software (Xenogen) and integrated over
5 min. For photon quantification, a region of interest
was manually selected and kept constant within all
experiments. Baseline imaging was performed 1 week
before stroke was induced and bioluminescence was
expressed as fold induction over baseline levels.
Estrus cycle determination
For determination of stage of estrus, sterile cotton swabs
moistened with saline were inserted into the vagina and
gently rotated. Swabs were then rolled onto glass slides
and allowed to dry. Polymorphonuclear lymphocytes
(PMNs) and epithelial cells were visualized with a Hema
3 Stat Pack (Fisher Cat#23-123-869) used according to
the manufactuer’s directions. Stage of estrus cycle was
determined based on the ratio of PMN’s to nucleated
and cornified epithlieal cells. Diestrus was defined as the
stage when cells consisted mainly of polymorphonuclear
lymphocytes (PMNs). Proestrus was defined as the stage
when nucleated and cornified epithelial cells were
observed, along with a few PMNs. Estrus was classified
as the stage when cornified epithelial cells were predo-
minant, and metestrus was defined as the stage when
cornified epithelial cells and PMNs were detected.
Infarct evaluation
To visualize the region of infarction, representative ani-
mals from each age group (n ≥ 5) were sacrificed at 24
hours post stroke and their brains processed for TTC
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and each slice was immersed in 1.5% TTC in PBS at
37°C for 15 minutes and then fixed in 10% formalin.
T h ea r e ao ft h ei p s i l a t e r a lh e m i s p h e r ea n dt h ea r e ao f
the infarct on each section was measured in a blinded
fashion using NIH ImageJ 1.43u. The measurements
were multiplied by the distance between sections (1
mm) and then summed over the entire brain to yield
volume measurements.
Immunoflorescence
Immunoflorescence was performed on PFA fixed free-
floating coronal brain sections (40 μm) using standard
techniques. The following primary antibodies were used:
anti-TGF-b1 (1:1000; Torrey Pines Biolabs, East Orange,
NJ), anti-pSmad2 (1:1000; Cat# AB3849, Millipore, Bill-
erica, MA); Milli-Mark Pan Neuronal marker (1:500;
Millipore, Billerica, MA); anti-GFAP (1:1000; Dako, Car-
pinteria, CA); anti-CD68 (1:1000; ABD Serotec, Raleigh,
NC); anti CAII (1:2000; ABD Serotec, Raleigh, NC) and
anti-b-dystroglycan (1:1000; Novacastra/Leica Microsys-
tems, Bannockburn, IL). For quantification of Milli-
Mark Pan Neuronal marker, CAII, CD68 and GFAP
colocalization with pSmad2, two sections from each
mouse spaced 300 μm apart were immunostained. From
each section four random fields of view in the penumbra
(40× objective) were analyzed. The total number of cells
positive for each cell marker was averaged and the per-
centage of each population that was also positive for
pSmad2 was calculated.
Western blotting
Unstroked and stroked brains were lysed in glo lysis
buffer (Promega). Protein concentrations were equalized
and lysates mixed with 4× NuPage LDS loading buffer
(Invitrogen). Samples were loaded onto 4-12% NuPage
Bis-Tris gels (Invitrogen) and subsequently transferred
onto PVDF membranes. Blots were incubated with rab-
bit polyclonal antibodies (1:1000) against pSmad2 (cat#
AB3849 from Millipore and cat# 3101 from Cell Signal-
ing) and actin (cat# A5060 Sigma-Aldritch) and horse-
radish peroxidase-conjugated goat anti-rabbit IgG as
secondary antibody. Protein signals were detected using
an ECL kit (Amersham Pharmacia Biotech) and band
intensities were quantified on the original digital image
using UN-Scan-It Gel 6.1.
Statistical analysis
Data was acquired in a blinded and unbiased fashion.
Data are expressed as mean +/- standard error of the
mean (SEM). Statistical analyses were performed with
Prism 5 software (GraphPad, San Diego, CA). Means
between two groups were compared with two-tailed,
unpaired Student’s t tests; comparisons of means from
multiple groups with one control were analyzed with
one-way ANOVA and Dunnet’s post hoc test.
Results
TGFb signaling in the brain is equivalent in males and
females and does not fluctuate with the estrus cycle
TGFb pathway activation is transmitted primarily
through the Smad system. Receptor-regulated Smads
(Smad 1, 2, 3, 5 or 8) are phosphorylated, associate with
a co-Smad (Smad 4) and translocate to the nucleus,
w h e r et h e yb i n dt oS m a db i n d i n ge l e m e n t s( S B E )t o
activate transcription of target genes [15,16]. SBE-
LucRT mice are TGFb reporter mice that express a
fusion protein consisting of luciferase (luc), red fluores-
cent protein (R) and thymidine kinase (T) under the
control of a SBE [13]. In these mice luciferase biolumi-
nescence is predominantly in the brain, reliably indicates
TGFb signaling, and can be followed in real time
[13,17]. To determine how comparable reporter gene
expression is between individual SBE-LucRT mice, and
if reporter gene expression fluctuates with gender and
the estrus cycle, we imaged nine female and 5 male
SBE-LucRT mice for ten days. To determine which
stage of the estrus cycle each female was in, a vaginal
smear was taken every day and stained with a modified
Wright-Giemsa stain. The number of polymorphonuc-
lear leukocytes (PMNs) present in each smear was com-
pared to the number of nucleated and cornifed
epithelial cells (Fig 1A). There was no significant differ-
ence in bioluminescence between each female or for
each stage of the estrus cycle (Fig 1B-D). We also found
reporter gene expression to be comparable between
male mice and equivalent to that of the females (Fig
1E). This indicates that bioluminescence in SBE-LucRT
mice is very comparable between individuals and that
TGFb signaling in the brain does not fluctuate with gen-
der or the estrus cycle.
TGFb signaling increases with age and stroke
The dMCAO model of stroke produces a small lesion in
the cortex with a clearly defined border and a small
penumbra. In line with previous reports infarct volume
was significantly larger in the aged mice and astrogliosis
(GFAP immunoreactivity) was accelerated (Fig 2A, B)
[18,19]. Bioluminescence in the 5 month old females
was increased 2 fold on day 1 post stroke, remained ele-
vated for 7 days post stroke and was localized to the
region of the infarct (Fig 2C). After 7 days TGFb signal-
ing began to return to baseline (Fig 2D). This fold
increase was similar in the 18 month old female mice
(Fig 2E), although the absolute amount of TGFb signal-
ing in the old mice was substantially higher (Fig 2F).
This is not surprising considering that the lesion was
much larger in the aged animals. However, TGFb
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Page 3 of 13Figure 1 TGF-b signaling in the brain does not fluctuate with the estrus cycle or gender and is equivalent between individuals.A . )
Images depicting each stage of the estrus cycle. Vaginal swabs were stained by a Hema 3 Stat Pack. B.) Average bioluminescence for each day
of the estrus cycle (n = 9). C.) Representative bioluminescence showing the consistency of reporter gene (luciferase) expression (4 females
shown). D.) Average bioluminescence from 9 females imaged for 10 days. There is no significant difference between individuals. E.) Average
bioluminescence from 5 males imaged for 10 days. There is no significant difference between individuals. Error bars, SEM.
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Page 4 of 13Figure 2 TGFb signaling in the brain increases with age and stroke. A.) Infarct volume and representative TTC images of the lesion 24 hours
following dCMAO (*p < 0.05). B.) Quantification of GFAP immunostain, showing that astrogliosis is accelerated in aged mice (*p < 0.05 compared
to 5 month old). C.) Representative bioluminescence showing reporter gene (luciferase) expression is increased after stroke compared to surgical
shams (2 females shown at 3 days post stroke). D.) Time course of TGFb signaling (luciferase induction) after stroke in 5 month old females
(*p < 0.05 compared to sham). E.) Time course of TGFb signaling (luciferase induction) after stroke in 18 month old females (*p < 0.05 compared
to sham). F.) Comparison of absolute values of bioluminescence between young and old mice, showing that TGFb signaling in the brain
increases at baseline and after stroke (*p < 0.05 compared to 5 month old). G.) Western blot to corroborate that TGFb signalling increases after
stroke. Two different antibodies for pSmad2 were used to confirm that pSmad2 is increased at day 7 after stroke. NS = no stroke, D7 = day 7
post stroke. All error bars for this figure are SEM.
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at baseline, demonstrating that in the absence of injury
TGFb signaling in the brain increases with age.
To confirm the increase in TGFb signaling we
detected by luciferase activity, we performed a western
blot on brain extracts from the ipsilateral hemisphere of
mice sacrificed before, and 7 days after stroke, for phos-
phorylated Smad2 (pSmad2), a downstream mediator of
TGFb s i g n a l i n g .T h ep S m a d 2a n t i b o d yw eu s e df o r
immunoflorescence (Millipore AB3849) detected a pro-
tein with the correct molecular weight for pSmad2 (58
kDa) and bound the same band as an alternative
pSmad2 antibody (Cell Signaling 3101; Fig 2G). This
verifies that the pSmad2 antibody we used for subse-
quent immunoflorescence is specific for pSmad2. In
accordance with our luciferase findings pSmad2 levels
were increased 7 days post stroke (Fig 2G).
In summary, TGFb signaling increases 2 fold after
dMCAO stroke, beginning on day 1 and peaking on day
7, this pattern of increase is preserved in old animals,
and absolute TGFb signaling in the non-injured brain
increases with age. We did not observe a gender differ-
ence in these findings or in infarct volume.
TGF-b1 is predominantly co-localized with CD68+ cells
after stroke
To determine which cell type is the likely source of
increased TGF-b1 production after stroke, brain sections
were stained with an anti-TGF-b1 antibody, colocalized
with markers for astrocytes (GFAP), neurons (Milli-
mark Pan-Neuronal marker), and monocytic immune
cells (CD68). Although TGF-b1 colocalized with all
three cell types it was predominantly co-localized with
CD68, which marks both activated microglia and macro-
phages. These cells were located in both the ischemic
penumbra and the stroke core. These data suggest that
endogenous microglia and invading macrophages are
the predominant cell types that make TGF-b1a f t e r
ischemic brain injury (Fig 3).
TGFb signaling in neurons, oligodendrocytes and
endothelial cells is unchanged by stroke
To determine which cells are responding to TGFb in the
uninjured brain and after stroke, brain sections from
mice sacrificed at days 1, 3, 7, 14 and 21 after stroke
and at 21 days after sham surgery were double-labeled
with anti-pSmad2, a marker of TGFb signaling, and
markers of neurons (Millimark Pan Neuronal marker),
oligodendrocytes (CAII), endothelial cells (b-dystrogly-
can), astrocytes (GFAP) and activated microglia and
macrophages (CD68). We found that neurons uniformly
respond to TGFb in the absence of injury and at all
time points after stroke, with 100% of neurons co-loca-
lizing with pSmad2 (Fig 4A and Fig 5A; see additional
file 1 to confirm colocalization by 3D reconstruction).
We also found that the majority (approximately 70%) of
oligodendrocytes consistently respond to TGFb in the
absence of injury and did not observe any differences
after stroke (Fig 4B and Fig 5B; see additional file 2 to
confirm colocalization by 3D reconstruction). There was
no qualitative difference in the intensity of colocalization
of pSmad2 with neurons or oliogdendrocytes, at any
time point after stroke. This data suggests that the
response of neurons and oligodendrocytes to TGFb is
unchanged by ischemic injury. Unlike neurons and oli-
godendrocytes, b-dystroglycan rarely colocalized with
pSmad2 in the absence of injury and after stroke, indi-
cating that endothelial cells in adult brain seldom signal
via pSmad2 in response to TGFb (Fig 4C; see additional
file 3 to confirm colocalization by 3D reconstruction).
This data was consistent across age and gender.
TGFb signaling increases in astrocytes and microglia/
macrophages after stroke
Although we found no difference in TGFb signaling in
neurons, oligodendrocytes and endothelial cells after
stroke, we did find a qualitative increase in TGFb signal-
ing in astrocytes and microglia/macrophages. In the days
following stroke, pSmad2 immunoflorescence became
brighter in the border of the lesion (Fig 6A) compared
to sham mice that showed even pSmad2 immunoflores-
cence throughout the cortex (Fig 6B). Concurrently,
GFAP and CD68 immunoreactivity increased in the
same location and the GFAP and CD68 positive cells
co-localized intensely with pSmad2 (Fig 7 &8; see addi-
tional files 4 and 5 to confirm colocalization by 3D
reconstructions). This was the case in young and old
mice of each gender and increased co-localization of
GFAP and CD68 with pSmad2 corresponded with the
profile of increased TGFb signaling after stroke we
observed by real time imaging (Fig 2C-F). These data
suggest that increased TGFb signaling in the brain after
stroke is due to responses from lesional and perilesional
astrocytes and monocytic lineage immune cells.
Discussion
We show here for the first time that TGFb signaling in
the brain increases in the first week after stroke in both
young and old mice. We incorporated 18 month old
mice into this study because nearly three quarters of all
strokes occur in people over the age of 65 and there is a
large knowledge gap regarding how mechanisms of
recovery change with age. Similarly, we performed this
study on mice of both genders in order to determine if
t h e r ei sas e xd i f f e r e n c ei nT G F b signaling after stroke.
In 5 month old mice, TGFb signaling increased 2 fold
over baseline in the first week after stroke, before begin-
ning to return to pre-stroke levels. This profile of
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mice, although the absolute level of TGFb signaling was
significantly higher in the older animals. This could be
in response to greater damage in the older animals as
we found that lesion size was over double the volume
compared to the younger mice. Baseline TGFb signaling
was also higher in the aged animals and so increased
TGFb signaling after stroke may also be a reflection of
their higher baseline level. Our finding that infarct
volume is increased in older animals conflicts with other
studies that report that infarct volume is not increased
in older subjects [18,20]. However, these studies used
the suture model of stroke, which causes a larger lesion
than the dMCAO model of stroke used here. Studies
that use a similar cortical model of stroke to the
dMCAO model find that lesion size is increased in aged
rats relative to young [19]. Therefore the impact of age
on lesion size appears to be stroke model dependent.
Every cell type in the brain has been shown to be cap-
able of making TGF-b1 and increases in TGF-b1 mRNA
have been demonstrated after stroke [1,21]. To discover
which cell type is predominantly responsible for post
stroke production of TGF-b1 we co-localized an anti-
TGF-b1 antibody with markers of different brain cell
types. We found that TGF-b1p r e d o m i n a n t l yc o -
localized with CD68, a marker of activated microglia
and macrophages, indicating that they are likely to be
the cells that produce it after stroke.
While there is ample evidence that TGFb production
is increased after stroke, as it is after many kinds of
brain injury, it was not known whether increased TGFb
production translates to an increased response, because
all TGFb isoforms are excreted as an inactive form that
lies inert in the extracellular matrix [22]. TGFb receptor
insertion into the membrane is highly regulated and the
intracellular Smad pathways that transmit TGFb signals
interact with a complex array of other kinase substrates
[23]. Therefore, although many of the proteins that acti-
vate TGFbs are upregulated after brain injury, such as
reactive oxygen species, metalloproteases, plasmin, and
thrombospondin [22], it was not known if increases in
TGF-b1 mRNA would correlate directly with increased
Figure 3 TGF-b1 is predominantly colocalized with CD68+ cells after stroke. Representative image (40×) showing CD68 (activated
microglia/macrophages) co-localized with TGF-b1 after stroke (images are from a young female mouse at day 3 post stroke.
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TGFb signaling was regulated differently in different cell
types after stroke.
TGF-b1 is strongly neuroprotective, at least in part
due to direct effects in neurons [11,24-28]. It is also
involved in synapse formation, the balance of excitatory
and inhibitory transmission in the hippocampus and
plasticity in multiple circuits [29]. We found that TGFb
signaling in neurons is widespread and consistent before
stroke and that there are no obvious quantitative or
qualitative differences after stroke. This suggests that
while TGFb signaling plays an important constitutive
function in neurons, the physiological role of increased
TGF-b1 after stroke may not be to signal to neurons.
Surprisingly, we also found that the majority of oligo-
dendrocytes in the brain are responding to TGFb in the
absence of injury and after stroke. This suggests that
TGFb signaling plays a physiological role in oligoden-
drocytes that was heretofore unappreciated. As with
neurons, co-localization of pSmad2 with oligodendro-
cytes did not increase after stroke suggesting that the
role of increased TGF-b1 after stroke is not to commu-
nicate to this cell type. Whether constitutive TGFb sig-
naling in oligodendrocytes is important for their
function or survival remains to be elucidated.
We rarely found co-localization of pSmad2 with
endothelial cells. Signal transduction by TGFb family
members is mediated via specific heteromeric complexes
of type I and type II serine/threonine kinase receptors.
In most cells TGFb signals via the type I receptor ALK5
but in endothelial cells it can also signal via the type I
receptor ALK1 [7,30]. ALK5 induces phosphorylation of
Smads 2 and 3 and ALK1 mediates phosphorylation of
Smads 1, 5 and 8. Endothelial cells may not co-localize
with pSmad2 due to the activation of the ALK1 path-
way. Thus endothelial cells may still respond to TGFb
in the brain at baseline and after stroke but by activa-
tion of the Smads downstream of ALK1.
Figure 4 TGFb signaling in neurons, oligodendrocytes and endothelial cells is unchanged by stroke. A.) Co-localization of pSmad2
(marker of TGFb signaling) with Millimark Pan-Neuronal antibody cocktail (marker of neurons) See additional file 1 for a 3D projection. B.) Co-
localization of pSmad2 with CAII (oligodendrocyte marker) See additional file 2 for a 3D projection. C.) Co-localization of pSmad2 with b-
dystroglycan (endothelial cell marker) See additional file 3 for a 3D projection. Images (40×) are from young females at day 3 post stroke but are
representative of all time points for both young and old, male and female mice.
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glia and macrophages respond in an autocrine manner
to the TGF-b1 they produce. We found that co-localiza-
tion of CD68 with pSmad2 increased in parallel with
TGFb signaling reporter gene expression after stroke.
TGFb can exert either anti-inflammatory or pro-inflam-
matory effects in a context-dependent fashion. However,
in the majority of contexts TGF-b1 appears to play an
anti-inflammatory role and moderate the production of
neurotoxic pro-inflammatory cytokines. It drives the dif-
ferentiation of regulatory T cells and M2c macrophages
that resolve immune responses, and resolves the inflam-
matory process in myocardial ischemia [7,31,32]. A
function of TGF-b1 after stroke may be to drive the dif-
ferentiation of monocytic lineage cells - both activated
microglia and macrophages - into an M2c phenotype to
enable a similar wound healing response to that identi-
fied in myocardial ischemia.
Our data also demonstrates that co-localization of
pSmad2 with activated astrocytes increases after stroke.
There is strong in vitro and in vivo evidence that TGFb
plays an important role in generating reactive astrogliosis,
and that reactive astrocytes participate in innate immune
responses. Overexpression of TGFb chronically leads to
reactive astrogliosis, and these mice display exacerbated
reactive astrogliosis in a stab wound model [33]. Injection
of TGF-b1 also increases reactive astrogliosis after stab
wound [34], while injection of neutralizing antibodies
inhibits expression of fibrogenic proteins, including
Figure 5 Co-localization of pSmad2 with neurons and
oligodendrocytes after stroke. A.) Both before and after stroke
100% of neurons in the cortex are co-localized with pSmad2 in
young and old mice. B.) Both before and after stroke ~70% of
oligodendrocytes in the cortex are co-localized with pSmad2 in
young and old mice.
Figure 6 pSmad2 immunoreactivity is increased in the stroke penumbra and colocalizes with CD68 and GFAP. Representative images
(10×) showing CD68 and GFAP colocalized with pSmad2 after stroke (image A is from a young female mouse at day 14 post stroke, image B is
from a young female mouse after sham surgery). There is a qualitative increase in pSmad2 immunoflorescence in the infarcted region (outlined)
with the brightest cells co-localizing with CD68 and GFAP.
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Page 9 of 13Figure 7 TGFb signaling in reactive astrocytes increases in the stroke penumbra after stroke. A.) Representative image (40×) showing
GFAP (astrocytes) colocalized with pSmad2 after stroke. Image is from a young female mouse at day 14 post stroke. See additional file 4 for a
3D projection B.) GFAP immunoreactivity increases in the first 7 days after stroke with the majority of astrocytes colocalizing with pSmad2 (*p <
0.05 compared to sham).
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Page 10 of 13Figure 8 TGFb signaling in activated microglia/macrophages increases in the stroke penumbra after stroke. A.) Representative image
(40×) showing CD68+ activated microglia and macrophages) co-localized with pSmad2 after stroke. Image is from a young female mouse at
day 3 post stroke. See additional file 5 for a 3D projection. B.) CD68 immunoreactivity increases in the first 3 days after stroke with the majority
of CD68+ cells co-localizing with pSmad2 (*p < 0.05 compared to sham).
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Finally, Smad3 knockout mice display faster wound heal-
ing and decreased scar formation after brain stab injury
[6]. Prior to this study no investigation addressed
whether it is TGFb signaling in astrocytes that leads to
reactive astrogliosis, but we show here that astrocytes do
respond to post stroke increases in TGFb.T o g e t h e rt h i s
supports the hypothesis that TGFb signaling in astrocytes
directly mediates astrogliosis after stroke. Astrogliosis
may have a detrimental effect on recovery due to astro-
cytes extending processes in the infarct border to encom-
pass the developing infarct, thereby inhibiting neuronal
plasticity and the formation of new axons and blood ves-
sels in the infarcted region [35].
As the brain ages it becomes characterized by a low
grade chronic pro-inflammatory state and responds with
an earlier and stronger innate immune response follow-
ing stroke [20]. We found that there is increased TGFb
signaling in the aged brain in the absence of injury and
this may be part of an anti-inflammatory strategy
employed by the aging brain to counter the primed pro-
inflammatory state. Our findings are consistent with
others who have shown that in aging the expression of
TGFb receptors increases, as does the expression of
TGF-b1 [2,20,36,37]. Conversely, since the data we pre-
sent here strongly suggests that TGFb signaling is
important for neuronal function, increased TGFb signal-
ing in the aged brain may be required to maintain nor-
mal neuronal function in the face of age related
changes. More research is needed to determine which of
these scenarios is correct.
Conclusions
These results show that TGFb signaling in the brain
does not oscillate with the estrus cycle and that it
increases 2 fold after the dMCAO model of stroke in
young and old animals of each gender. Astrocytes and
CD68+ innate immune cells are the cell types that
respond to increased levels of TGFb after stroke and
they do so during the first week after stroke, coincident
with glial scar formation. Given TGFbs effects on mono-
cytic lineage cells and astrocytes we hypothesize that the
role of increased TGFb signaling after stroke is to regu-
late glial scar formation and the polarization of invading
innate immune cells and resident microglia.
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